Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
8 - The newly diagnosed patient with polycythemia vera
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 64 - 69Publisher: Cambridge University PressPrint publication year: 2016
References
Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Vardiman, JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.Google Scholar
Tefferi, A, Thiele, J, Vannucchi, AM, Barbui, T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–13.CrossRefGoogle Scholar
Barbui, T, Thiele, J, Vannucchi, AM, Tefferi, A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014;28(6):1191–5.CrossRefGoogle ScholarPubMed
Vainchenker, W, Delhommeau, F, Constantinescu, SN, Bernard, OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723–35.CrossRefGoogle ScholarPubMed
Rotunno, G, Mannarelli, C, Guglielmelli, P, Pacilli, A, Pancrazzi, A, Pieri, L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–5.CrossRefGoogle ScholarPubMed
Rumi, E, Pietra, D, Ferretti, V, Klampfl, T, Harutyunyan, AS, Milosevic, JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51.CrossRefGoogle ScholarPubMed
Spivak, JL, Silver, RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231–9.CrossRefGoogle ScholarPubMed
McMullin, MF, Reilly, JT, Campbell, P, Bareford, D, Green, AR, Harrison, CN, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138(6):821–2.CrossRefGoogle Scholar
Tefferi, A, Thiele, J, Vannucchi, AM, Barbui, T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–13.CrossRefGoogle Scholar
Silver, RT, Chow, W, Orazi, A, Arles, SP, Goldsmith, SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013;122(11):1881–6.CrossRefGoogle ScholarPubMed
Barbui, T, Thiele, J, Carobbio, A, Guglielmelli, P, Rambaldi, A, Vannucchi, AM, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014;89(6):588–90.CrossRefGoogle ScholarPubMed
Barbui, T, Carobbio, A, Rumi, E, Finazzi, G, Gisslinger, H, Rodeghiero, F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021–3.CrossRefGoogle ScholarPubMed
Martinelli, I, De Stefano, V, Carobbio, A, Randi, ML, Santarossa, C, Rambaldi, A, et al. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. an European LeukemiaNet study. Am J Hematol. 2014;89(11):E200–5.CrossRefGoogle Scholar
Barbui, T, Carobbio, A, Rambaldi, A, Finazzi, G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759–63.CrossRefGoogle ScholarPubMed
Vannucchi, AM, Antonioli, E, Guglielmelli, P, Longo, G, Pancrazzi, A, Ponziani, V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952–9.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Landolfi, R, Kutti, J, Gisslinger, H, Patrono, C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.CrossRefGoogle Scholar
Barosi, G, Birgegard, G, Finazzi, G, Griesshammer, M, Harrison, C, Hasselbalch, H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–3.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.CrossRefGoogle ScholarPubMed
Kiladjian, J-J, Mesa, RA, Hoffman, R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706–15.CrossRefGoogle ScholarPubMed
Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.CrossRefGoogle ScholarPubMed